

Discover, Develop, Deliver: Building a Successful Start-Up in the Midst of a Pandemic



Wendy Naimark, PhD

Chief Technology Officer
Ripple Therapeutics


Tuesday, Jan 26, 2021

11:00 am - 12:00 pm

Join the webinar:

<https://us02web.zoom.us/j/88082675085?pwd=UXUxOXhhRXZVUmhIMFBXS21VY1p1QT09>

Meeting ID: 880 8267 5085; Password: xDHR1g



UNIVERSITY OF
TORONTO



Biography

Dr. Naimark is one of the founders of Ripple Therapeutics (RIPL) following its spin out from Interface Biologics (IBI) in 2020. Dr. Naimark has been leading teams in the development of local drug delivery products for over 20 years. She joined IBI in 2016 and led the Research & Development of both Epidel and Kinesyx technology teams and partner projects. Prior to joining IBI, Dr. Naimark led the Clinical Program for the development of a drug-eluting, self-expanding, biodegradable scaffold at 480 Biomedical. Dr. Naimark began her industry career at Boston Scientific in the Corporate R&D group, which developed the TAXUS® Drug Eluting Stent. At Boston Scientific her work spanned developing combination products to deliver angiogenic biological agents to leading Regulatory Submission Strategies for approval of Class III combination products. Dr. Naimark received her PhD in Biomaterials from the University of Toronto and began developing her career interest in local drug delivery at Caltech during her post-doctoral fellowship. Dr. Naimark is an inventor of 29 patents in the local drug delivery field.

Abstract

Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery. Ripple's Epidel® technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without polymers or excipients.

<https://www.rippletherapeutics.com/>